IRIS
AVENALI, MICOL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.924
AS - Asia 1.532
EU - Europa 1.144
SA - Sud America 309
AF - Africa 84
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.000
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.868
CN - Cina 482
SG - Singapore 413
IT - Italia 249
BR - Brasile 235
IE - Irlanda 234
HK - Hong Kong 217
RU - Federazione Russa 184
VN - Vietnam 163
DE - Germania 136
FR - Francia 89
FI - Finlandia 71
BD - Bangladesh 68
ZA - Sudafrica 53
IN - India 51
GB - Regno Unito 49
CA - Canada 27
NL - Olanda 24
AR - Argentina 21
JP - Giappone 20
MX - Messico 19
PL - Polonia 17
CO - Colombia 16
ID - Indonesia 15
IQ - Iraq 14
CZ - Repubblica Ceca 11
PK - Pakistan 11
SE - Svezia 11
ES - Italia 10
MA - Marocco 10
TR - Turchia 10
UA - Ucraina 10
AT - Austria 8
EC - Ecuador 8
JO - Giordania 8
PH - Filippine 8
VE - Venezuela 8
BE - Belgio 7
AL - Albania 6
CL - Cile 6
KG - Kirghizistan 6
MY - Malesia 6
PY - Paraguay 6
UZ - Uzbekistan 6
AU - Australia 5
MO - Macao, regione amministrativa speciale della Cina 5
CH - Svizzera 4
EG - Egitto 4
KE - Kenya 4
KR - Corea 4
SA - Arabia Saudita 4
UY - Uruguay 4
BO - Bolivia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
KZ - Kazakistan 3
LT - Lituania 3
RO - Romania 3
RS - Serbia 3
SI - Slovenia 3
TN - Tunisia 3
AZ - Azerbaigian 2
DK - Danimarca 2
DZ - Algeria 2
GR - Grecia 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NP - Nepal 2
PE - Perù 2
SN - Senegal 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KH - Cambogia 1
LC - Santa Lucia 1
MD - Moldavia 1
MM - Myanmar 1
MQ - Martinica 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
VC - Saint Vincent e Grenadine 1
Totale 5.000
Salva come PNG Salva come JPEG
Città #
San Jose 265
Dublin 223
Singapore 220
Hong Kong 214
Chandler 213
Dallas 175
Ashburn 162
Beijing 129
Boardman 80
Los Angeles 76
Ho Chi Minh City 54
New York 52
Lauterbourg 51
Helsinki 48
Johannesburg 47
Munich 41
Council Bluffs 40
Milan 39
Hanoi 38
Rome 37
Shanghai 37
Moscow 36
Princeton 33
Lawrence 31
Medford 29
Nanjing 29
Redondo Beach 28
Wilmington 27
São Paulo 26
Orem 24
Santa Clara 24
Buffalo 21
Frankfurt am Main 20
Turku 18
Hebei 17
Tokyo 17
Warsaw 17
The Dalles 16
Nuremberg 15
Chennai 14
Nanchang 14
Amsterdam 13
Brooklyn 13
Jacksonville 13
Hangzhou 12
Falkenstein 11
London 11
Naples 11
Pavia 11
Seattle 11
Shenyang 11
Düsseldorf 10
Haiphong 10
Rio de Janeiro 10
Chicago 9
Fairfield 9
Florence 9
Houston 9
Montreal 9
Toronto 9
Amman 8
Changsha 8
Norwalk 8
Stockholm 8
Ann Arbor 7
Belo Horizonte 7
Boston 7
Brno 7
Columbus 7
Menlo Park 7
Mexico City 7
Tianjin 7
Baghdad 6
Bishkek 6
Cagliari 6
Da Nang 6
Les Paris 6
Medellín 6
Poplar 6
Pune 6
Tashkent 6
Bakersfield 5
Biên Hòa 5
Brussels 5
Denver 5
Elk Grove Village 5
Falls Church 5
Fortaleza 5
Guangzhou 5
Hyderabad 5
Macao 5
Mumbai 5
Phoenix 5
Tirana 5
Tübingen 5
Washington 5
Ankara 4
Atlanta 4
Bogotá 4
Camden 4
Totale 3.131
Salva come PNG Salva come JPEG
Nome #
CLINICAL AND BIOCHEMICAL SIGNATURES OF GBA-RELATED PARKINSON DISEASE 166
Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy 151
Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism 143
A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value 131
Consensus on the treatment of dysphagia in Parkinson's disease 130
Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study 127
Body Weight Support Combined With Treadmill in the Rehabilitation of Parkinsonian Gait: A Review of Literature and New Data From a Controlled Study 127
Time for a consensus conference on pain in neurorehabilitation 121
What is the role of the placebo effect for pain relief in neurorehabilitation? Clinical implications from the Italian consensus conference on pain in neurorehabilitation 120
KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset 120
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 112
Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. 111
Extracellular Vesicles Derived From Plasma of Patients With Neurodegenerative Disease Have Common Transcriptomic Profiling 111
Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project 109
Botulinum toxin for chronic migraine: Clinical trials and technical aspects 109
Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes 109
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol 106
Blood D-serine levels correlate with aging and dopaminergic treatment in Parkinson's disease 106
Different miRNA profiles in plasma derived small and large extracellular vesicles of neurodegenerative disease patients. 106
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 106
The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait 102
Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis 101
Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy 100
Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation 93
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 90
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 89
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 83
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 80
Harmonic ratio is the most responsive trunk-acceleration derived gait index to rehabilitation in people with Parkinson’s disease at moderate disease stages 79
A narrative review on the role and main findings of the Videofluoroscopic Study of Swallowing in Parkison's disease 78
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 78
Apomorphine Subcutaneous Infusion Likely Induced Acute Thrombocytopenia in a Patient with Parkinson's Disease and Motor Fluctuations 70
Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort 69
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort 67
Serum dysregulation of serine and glycine metabolism as predictive biomarker for cognitive decline in frail elderly subjects 66
Bilateral Dentate Nuclei Hyperintensities and Response to 4-Aminopyridine in a Patient With Childhood-Onset GAA- FGF14 -Related Ataxia 64
Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease? 62
Exploring the neural and behavioral correlates of cognitive telerehabilitation in mild cognitive impairment with three distinct approaches 61
From DYMUS to DYPARK: Validation of a Screening Questionnaire for Dysphagia in Parkinson’s Disease 61
Pearls & Oy-sters: Marionette Walk in Parkinson Disease 60
Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: A 6-year longitudinal study 59
Non-Invasive Neuromodulation in the Rehabilitation of Pisa Syndrome in Parkinson's Disease: A Randomized Controlled Trial 58
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) 57
Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial 57
The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease 56
Psychological treatments and psychotherapies in the neurorehabilitation of pain: Evidences and recommendations from the italian consensus conference on pain in neurorehabilitation 55
CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants 54
Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis 52
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells 52
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study 50
Functional Study of SNCA p.V15A Variant: Further Linking α-Synuclein and Glucocerebrosidase 49
Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project 49
Reply to: “Increased alpha-Synuclein Level in CD45+ Blood Cells in Asymptomatic Carriers of GBA Mutations” 48
Parkinson disease following COVID-19: Report of six cases 47
Proprioceptive Focal Stimulation (Equistasi®) May Improve the Quality of Gait in Middle-Moderate Parkinson's Disease Patients. Double-Blind, Double-Dummy, Randomized, Crossover, Italian Multicentric Study 46
LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients 45
Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale 44
Pain in focal dystonias - A focused review to address an important component of the disease 37
Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease 32
Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach 31
null 30
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study 28
Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer’s dementia 25
1H-NMR-based metabolomics identifies disrupted betaine metabolism as distinct serum signature of pre-frailty 10
Clustering Algorithm Reveals Dopamine-Motor Mismatch in Cognitively Preserved Parkinson's Disease 7
The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study 6
RAB32 mutation in Parkinson's disease [2] 5
Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation 4
The treatment of axial and foot dystonia 4
Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals 4
Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant 3
Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review 3
Initiating foslevodopa infusion in Parkinson disease: a pragmatic study 3
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials 3
Domain-driven verbal and non-verbal dissociations in cognition and social cognition in Parkinson’s disease 3
LONG-NEXT: A new accurate and efficient NGS-based method for GBA1 analysis in Parkinson disease 2
Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, “Real-World” Study. The EPIC Study 2
Asymmetric Parietal Cortical Atrophy in a Patient with RAB39B-Associated Parkinsonism 2
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies 2
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease 2
Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker 2
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients 2
RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria 1
Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study 1
Totale 5.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.312
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.312
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/2022181 0 1 1 16 9 12 3 13 10 1 20 95
2022/2023571 57 54 5 69 33 46 1 22 258 3 15 8
2023/2024360 37 48 8 22 11 70 29 24 2 11 50 48
2024/20251.139 39 59 21 21 44 116 127 63 260 61 123 205
2025/20262.627 196 191 268 252 287 91 440 139 267 207 190 99
Totale 5.106